Literature DB >> 24112261

Autologous serum eye drops for the treatment of persistent corneal epithelial defects.

Muhammad Aamir Arain1, Asad Jamal Dar, Lubna Adeeb.   

Abstract

A series of 10 patients at Armed Forces Institute of Ophthalmology, Rawalpindi, from September 2009 to August 2010 is reported. Follow-up of patients were done till February 2012. Patients with persistent corneal epithelial defects (PED) of minimum 2 weeks duration, in whom conventional therapy had failed, were included in the study. They were prescribed 100% autologous serum eye drops on hourly basis. When PED healed within 02 weeks, it was labeled as effective and when it healed within one month, it was labeled as partially effective. Six weekly follow-up was done for 18 months for all patients to document any recurrence of PED. Eight out of 10 patients had successful outcome i.e. 80% of PED healed within one month, out of which 7 patients had 'effective' outcome. Autologous serum eye drops are safe, effective and minimally invasive modality in treating PED.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24112261     DOI: 10.2013/JCPSP.737739

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  3 in total

1.  Human growth hormone promotes corneal epithelial cell migration in vitro.

Authors:  Juan Ding; Barbara Wirostko; David A Sullivan
Journal:  Cornea       Date:  2015-06       Impact factor: 2.651

2.  Non-steroidal anti-inflammatory drug delays corneal wound healing by reducing production of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B4 receptor 2.

Authors:  Satoshi Iwamoto; Tomoaki Koga; Mai Ohba; Toshiaki Okuno; Masato Koike; Akira Murakami; Akira Matsuda; Takehiko Yokomizo
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

Review 3.  Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis.

Authors:  Maria Rosaria De Pascale; Michele Lanza; Linda Sommese; Claudio Napoli
Journal:  J Ophthalmol       Date:  2015-10-04       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.